Selecta Biosciences (SELB) Misses Q3 EPS by 19c

Selecta Biosciences (NASDAQ: SELB) reported Q3 EPS of ($0.09), $0.19 worse than the analyst estimate of $0.10.

“This past quarter has been productive for our team as we have continued to progress our clinical programs,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “We reported topline data from the Phase 2 COMPARE trial of SEL-212 which demonstrated the potential of our ImmTOR platform when combined with a highly immunogenic enzyme, and we commenced the Phase 3 DISSOLVE program in partnership with Sobi. We look forward to continuing to build our pipeline with our gene therapy programs in MMA and OTC deficiency, and our second enzyme program in IgA nephropathy. Our strategy is focused on leveraging ImmTOR to amplify the efficacy of biologic therapies and restore self-tolerance in autoimmune diseases.”

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance